Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
$221K Sell
34,354
-550
-2% -$4.89K ﹤0.01% 1186
2024
Q4
$332K Buy
34,904
+550
+2% +$4.83K ﹤0.01% 1060
2024
Q3
$281K Sell
34,354
-95
-0.3% -$987 ﹤0.01% 1121
2024
Q2
$466K Buy
34,449
+163
+0.5% +$1.36K ﹤0.01% 938
2024
Q1
$240K Sell
34,286
-98
-0.3% -$851 ﹤0.01% 1121
2023
Q4
$377K Sell
34,384
-29
-0.1% -$285 ﹤0.01% 977
2023
Q3
$378K Buy
34,413
+104
+0.3% +$1.49K ﹤0.01% 930
2023
Q2
$448K Hold
34,309
﹤0.01% 862
2023
Q1
$448K Buy
34,309
+17,166
+100% +$141K ﹤0.01% 867
2022
Q4
$187K Buy
+17,143
New +$211K ﹤0.01% 1109

Other funds holding ENVX

Glenmede Trust's ENVX Position: Q1 2025 in Review

Glenmede Trust reduced its Enovix (ENVX) stake by 1.6% in Q1 2025, selling an estimated $4.89K and leaving 34,354 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #1186.

Glenmede Trust first reported a position in ENVX in Q4 2022 and has held it in 10 quarters since. The position peaked at $466K in Q2 2024. 315 funds tracked by Wall St. Rank hold ENVX as of Q1 2025.

  • Glenmede Trust held 34,354 shares of Enovix worth $221K as of Q1 2025.
  • Glenmede Trust sold 550 Enovix shares in Q1 2025, an estimated $4.89K.
  • Enovix made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2025, its #1186 holding.
  • Glenmede Trust first reported a position in Enovix in Q4 2022 and has held it in 10 quarters since.
  • Glenmede Trust's Enovix position peaked at $466K in Q2 2024.
  • 315 funds tracked by Wall St. Rank held Enovix as of Q1 2025.

Based on Glenmede Trust's 13F filing for Q1 2025, filed 15 May 2025.